Stocktoria
Zymeworks Inc. ZYME
Zymeworks Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M | $26.7M |
| R&D expense | — | — | $143.6M | $208.6M | $199.8M |
| Operating income | -$92.5M | -$137.1M | -$138.1M | $130.5M | -$215.6M |
| Income tax | $1.4M | $6.1M | -$568,000 | $10.9M | -$516,000 |
| Net income | -$81.1M | -$122.7M | -$118.7M | $124.3M | -$211.8M |
| EPS (diluted) | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
| Operating cash flow | -$33.0M | -$110.1M | -$118.3M | $144.1M | -$192.5M |
| Free cash flow | -$34.5M | -$112.0M | -$120.8M | $136.0M | -$204.9M |
| Cash & equivalents | $41.2M | $66.1M | $157.6M | $400.9M | $201.9M |
| Total assets | $346.5M | $463.1M | $580.9M | $648.7M | $389.1M |
| Total liabilities | $78.0M | $124.3M | $116.1M | $155.8M | $140.0M |
| Shareholders' equity | $268.5M | $338.8M | $464.8M | $493.0M | $249.1M |
Growth · year-over-year · Revenue CAGR 41.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | +38.9% | +0.4% | -81.6% | +1446.0% | — |
| Net income growth | — | — | -195.4% | — | — |
| EPS growth | — | — | -190.5% | — | — |
| Free cash flow growth | — | — | -188.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.